Aridis Pharmaceuticals Respiratory Health Investor Presentation 2022

Late-stage clinical biotech company presenting Phase 3 programs in respiratory health, including first-in-class acute pneumonia treatment and prevention candidates with ~$1 billion market opportunity. Deck highlights strong Phase 2 clinical data, seasoned management, and upcoming 2H2022 clinical readouts.